ISPUB.com / IJPHARM/7/1/11726
  • Author/Editor Login
  • Registration
  • Facebook
  • Google Plus

ISPUB.com

Internet
Scientific
Publications

  • Home
  • Journals
  • Latest Articles
  • Disclaimers
  • Article Submissions
  • Contact
  • Help
  • The Internet Journal of Pharmacology
  • Volume 7
  • Number 1

Original Article

Cyclooxygenase isoforms in health and disease

A Saqib, C Karigar

Keywords

alzheimer’s disease, arthritis, cancer, cyclooxygenase, inflammation, parkinson’s disease, prostaglandins

Citation

A Saqib, C Karigar. Cyclooxygenase isoforms in health and disease. The Internet Journal of Pharmacology. 2008 Volume 7 Number 1.

Abstract

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have long been used for the treatment of pain and inflammation owing to their inhibitory effects on cyclooxygenase (COX). Ever since NSAIDs have been in use, multiple adverse effects have been noted. Assessment of many of these effects has been complicated due to the discovery of multiple splice variants of the COX gene, greater array of COX and specific COX-2 inhibitor availability. The effect of these drugs on COX cannot be readily explained. This has sparked a new field of investigation on splice variants of COX and effects of COX inhibitors. This review summarizes our current understanding of the role of cyclooxygenase in health and disease.

 

Introduction

The mechanism of action of NSAIDs has long been proposed based on their inhibition of prostaglandin biosynthesis, enzyme cyclooxygenase (COX or prostaglandin H2 synthase). Two decades after COX discovery the existence of at least two COX isoforms; COX-1 and COX-2 were demonstrated in 1990 (Figure 1). Currently the research is focused on developing safer NSAIDs based on their mechanisms of action and physiological roles in the pathogenesis of inflammation. New classes of COX-2 selective inhibitors have entered the worldwide market. These new medications offer safer alternatives to NSAIDs in terms of gastrointestinal safety; however, toxicological concerns regarding their renal and cardiovascular safety remain. These COX-2 specific inhibitors benefit arthritic patients, slow down tumor growth, delay the birth process, and impede degenerative changes associated with Alzheimer’s disease and Parkinson’s disease. There has been much speculation in the field on the possibility of a third COX isoform COX-3, that is potently inhibited by some NSAIDs. Thus, inhibition of COX-3 could represent an additional mechanism by which these drugs decrease pain and possibly fever.

Figure 1
Figure 1: Mechanism of Action of COX

Prostaglandins are widely distributed in human tissues (1). PGs encoded by an early response gene not only play a central role in inflammation, but also regulate other critical physiological responses. In humans, PGs are involved in diverse functions, such as blood clotting, ovulation, initiation of labor, bone metabolism, nerve growth and development, wound healing, kidney function, blood vessel tone, and immune responses.

Unlike cortisone or thyroxin, PGs are synthesized in a broad range of tissue types and serve as autocrine or paracrine mediators to signal changes within the immediate environment. Two classes of prostaglandin receptors exist to transduce signals upon binding of ligand. The G-coupled cytoplasmic receptor class (i.e., EP1-4 for PGE2) and the nuclear PPAR receptor class (i.e., PPARa, PPARg, PPARd), which act directly as transcription factors upon ligand binding (2). As PGs play broad roles in normal human physiology, it is not surprising that systemic suppression of PG synthesis through inhibition of COX can lead to unwanted side effects. In particular, individuals on NSAIDs treatment for even short periods can experience gastrointestinal and renal side effects (3, 4) in addition to effects on other physiological systems. The different effects of PGs can be explained by considering their varied chemistry, the diversity of PG receptors, and modulation of PG synthesis by local upstream and downstream effects. Prostaglandin isomers - including thromboxane and prostaglandins D2, E2, F2α, and I2 function in numerous physiological and pathophysiological processes, such as pyresis (fever), analgesia (sensitivity to pain), inflammation, thrombosis, parturition, mitogenesis, vasodilation and vasoconstriction, ovulation, and renal function. Prostaglandin isomers act upon G-protein-coupled receptors (5) and there are multiple receptors for some isoforms (such as prostaglandin E2). Prostaglandins are short-lived in vivo (with half-lives of seconds to minutes), and act in an autocrine or a paracrine rather than an endocrine fashion.

COX-1 was first studied in tissue and cell homogenates, and in this context was shown by Vane (6) to be the inhibitory target of NSAIDs. An intense amount of research conducted in the last decade has been devoted to assign distinguishing role for each type of COX isoforms. Investigators studying cell signaling pathways identified a unique, inducible gene product related to the known COX sequence (7). Concurrently, investigators looking at PG production in response to cytokines and other inflammatory factors noted increases in COX activity that could only be accounted for by increased expression of another COX (8). Both immunoprecipitation of this COX variant with an anti COX antibody, as well as the production of an antibody that precipitated only the COX-2 isoform, allowed for the identification of two different COX isoforms. It was subsequently determined that the COX-1 and COX-2 proteins are derived from distinct genes that diverged well before birds and mammals (9). In a nutshell these early studies revealed that both enzymes carry out essentially the same catalytic reaction and similar protein structures (10). Many of the inflammatory, inducible effects of COX appeared to be mediated by the newly discovered COX-2, while the ‘housekeeping’ effects of COX appear to be mediated by COX-1. This function for each isoform is consistent with their tissue expression patterns. All normal tissues express COX-1 with low to undetectable levels of COX-2 while, COX-2 is constitutively expressed in the brain and kidney of rodents. Other differences between COX-1 and COX-2 include differences in utilization of arachidonic acid substrate pools as well as in mRNA stability (11, 12).

The regions regulating gene expression of COX-1 and COX-2 show little similarity. For example, the promoter and enhancer regions regulating COX-2 contain a variety of response elements which play partial role in their inducibility by hormones, growth factors, phorbol esters, cAMP, inflammatory factors and cytokines. However, much less is known about the elements involved in regulating COX-1 gene expression, although several studies have reported induction of COX-1 in differentiation of macrophages (13–16). COX-1 and COX-2 also show major differences in mRNA splicing, stability, and translational efficiency.

Regulation of COX-2 at the mRNA level appears to be an important mechanism by which some physiological mediators, like corticosteroids, act to regulate PG production. Another major difference between COX-1 and COX-2 appears to be in their ability to choose different substrate pools. For example, in both fibroblasts and immune cells, COX-2 was able to utilize endogenous arachidonic acid, whereas COX-1 does not. In these systems, COX-1 requires exogenous substrate. Soluble PLA2 can produce an alternative source of substrate for COX-1. Herschman (17) has suggested that release of sPLA2 in some tissues from neighboring cells might provide the primary regulation of COX-1 activity. Thus, the regulatory elements responsible for increasing PG production are sPLA2 gene. In summary, the COX-1 and COX-2 genes are regulated by two independent and quite different systems even though the enzymatic reaction they catalyze is identical. The protein encoded by human and rat COX-3 gene has a completely different amino acid sequence than COX-1 and COX-2. It does not have COX activity; and distinguished as COX variant protein (COVAP) to differentiate it from the known prostaglandin synthesizing COX isoforms (18) the results from dog studies were extrapolated to humans and rodents without critical evaluation of the data.

COX Enzymes

Cyclooxygenase-1 (COX-1)

COX-1 is ubiquitously expressed in tissues under basal conditions (19). This implicates that COX-1 plays a major role in providing PG precursors for homeostatic regulation. One important site of COX-1 function is the blood platelets, where it is responsible for supplying precursors for thromboxane biosynthesis (20). This makes sense, since platelets, do not have nuclei, they cannot produce an inducible enzyme in response to activating conditions. Rather, platelets carry a supply of COX-1 in presence of an NSAID like aspirin; platelets are prevented from generating thromboxane during activation and fail to aggregate, inhibiting their thrombogenic potential. In the adjacent vascular endothelium, PGs play a different role. The release of eicosanoids by activated platelets is thought to provide both a substrate and stimulus for the generation of prostacyclin (PGI2) by the endothelium which stimulates vasodilatation, counteracting thromboxane a vasoconstrictor. COX-1 appears to have role in two other physiological systems: kidney and the stomach, leading to their vasodilatation in the presence of contractile conditions. In these systems, normal physiological stimuli are associated with dramatic changes in blood flow, during times of lowered blood volume, the kidney releases angiotensin and other factors to maintain blood pressure by systemic vasoconstriction (21). At the same time, angiotensin causes PG biosynthesis in the kidney.

COX-1 is expressed in the vasculature, glomeruli, and collecting ducts of the kidney, and it appears to be important in producing the vasodilating PGs, which maintain renal plasma flow and glomerular filtration rate (GFR) during conditions of systemic vasoconstriction. In the presence of NSAIDs, this protective response fails, leading to renal ischemia and damage in susceptible individuals (22). Similarly, in the gastric antrum, NSAID intake leads to ischemia followed by mucosal damage and ulceration (23). The enzyme blocked by NSAIDs is thought to be COX-1 (24) that produces PGs involved in altering blood flow in the microcirculation of the gastric mucosa. Thus, COX-1 acts in a variety of settings to maintain homeostatic levels of PGs. In some cases, induction of PLA2 is responsible for increased PG biosynthesis and in others, COX-1 levels are modulated (macrophages begin to differentiate). It is not yet clear whether all cells and tissues with COX- 1 rely on exogenous supplies of substrate, but this situation would allow for a variety of cooperative mechanisms linking COX-1 activity to neighboring physiological requirements.

Cyclooxygenase-2 (COX-2)

In studying a rabbit kidney model of inflammation, (25) it was noted that when one ureter was tied off causing inflammation, that kidney produced high levels of prostaglandins above the normal baseline production of the normal kidney. They also observed that when dermal fibroblasts were stimulated with lipopolysaccharide (LPS) or endotoxin in tissue culture, the same increase in prostaglandin production was observed. This excess prostaglandin could be inhibited by glucocorticoid and indomethacin. The postulation that a second enzyme system existed was based on the fact that excess prostaglandin could be produced in models of inflammation, that it was inhibited by inhibitors of protein synthesis as well as glucocorticoid, and that the baseline prostaglandin production was not affected by glucocorticoid. This second enzyme system COX-2 was considered to be inducible and upregulated by inflammatory stimuli such as cytokines.

The understanding on the mechanism of action of COX enzyme and its influence on rapid enhancement of PG during inflammation and in other physiological contexts came from studies on cell division. Simmons (26) and Herschman (25) groups independently identified the immediate early genes in fibroblast like cells activated by mitogens. Genes from chicken (27, 29) and mouse (30) were activated by the v-src oncogene, phorbol esters and serum. Use of Swiss 3T3 cells showed induction of tetradecanoyl-13-phorbol acetate inducible sequences (or TIS genes) that also induced by other mitogens (31). These workers independently reported that one of their sequences encoded a new inducible COX enzyme, which contributed to the identification of COX-2 in 1991. The inducible enzyme cloned in these studies was frequently referred to as COX-2 and the seminal vesicle form of the enzyme as COX-1.

One of the first studies conducted after the discovery of the isoform of COX was to screen against existing NSAIDs for differential inhibitory effects, and indeed some were found to have a 20 - 70 fold selective preference (28, 29). As a result, studies were conducted to find differential inhibition of COX-1 or COX-2 activities under a variety of experimental conditions (Table 1). While initial studies upheld the concept that COX-2 is mainly an inflammatory, inducible enzyme, more recent studies are beginning to reveal more functions (15).

Figure 2
Table 1: Profile of cyclooxygenase (COX) enzymes

Cyclooxygenase-3 (COX-3)?

A third isoform of COX, COX-3 was discovered in canine by Dan Simmons and colleagues while looking for the mechanism of action of acetaminophen. Acetaminophen is often categorized NSAID, even though in clinical practice and in animal models it possesses little antiinflammatory activity like NSAIDs (31), however acetaminophen inhibits pain and fever and is one of the world’s most popular analgesic and antipyretic drug. Despite acetaminophen’s long use and popularity it lacks a clear mechanism of action. Flower and Vane showed that acetaminophen inhibited COX activity in dog brain homogenates more than in homogenates from spleen (32). This gave rise to the concept that variants of COX enzymes exist that are differentially sensitive to this drug and acetaminophen acts centrally. Yet, even though two isozymes of COX are known, neither isozyme is sensitive to acetaminophen at therapeutic concentrations of the drug in whole cells or homogenates. Instead, COX-1 and COX-2 in homogenates frequently exhibit the paradoxical property of being stimulated by sub-millimolar concentrations of acetaminophen and inhibited by very high levels of the drug. This finding suggests that neither isozyme is a good candidate for the action of acetaminophen. While analyzing COX-1 and COX-2 RNA expression it was observed that cerebral cortex of dog brain contains two distinct RNAs that hybridized to a canine COX-1 cDNA (32).

Most experimental data conclude that COX-3 is just another COX-1 splice variant (33, 34). COX-3 is inhibited by acetaminophen but its general low expression level and the available kinetic data indicate that it is unlikely to be clinically relevant. Although several years have passed since the original publication (35), there is no any follow up study which would confirm the COX activity of the canine COX-3 and its sensitivity to acetaminophen. In human and rodents the mRNA transcript of COX-3 is potentially targeted by nonsense mediated decay, which explains its low expression level. The exact function of the COX-3 protein is currently unknown. COX-3 proteins from dog, human and rodents do not show substantial homology. Although COX-3 encoded proteins are known in rodents (33) and in human, their biological roles are unclear. The protein encoded by human and rat COX-3 gene has a completely different amino acid sequence than COX-1 and COX-2. Further COX-3 does not have usual COX activity hence it was distinguished as COX variant protein (COVAP) to differentiate it from the known COX isoforms (18). But evidence does not support claims (36, 37, 38) that acetaminophen is a selective COX-3 inhibitor in rodent studies. It is also important to note that commercially available anti-COX-3 antibodies can only be used in a species selective manner because of considerable differences among amino acid sequences of COX-3 from different species. The exact mechanism of acetaminophen still remains a mystery. Thus studying the transcription of COX genes might help us to better understand the function of alternative splicing mechanisms in eukaryotes.

Systemic Functions Of COX Isoforms

Kidney Physiology

Prostaglandins serve as important physiological modulators of vascular tone and sodium and water homeostasis in the mammalian kidney. COX-1 is recognized to be involved in normal kidney function, while COX-2 has a specific role. The localization studies indicate that COX-2 is expressed both in the macula densa of the kidney (39) and in the interstitial cells of the medulla in rats (40). The macula densa plays an important role in mediating interactions in glomerular filtration, proximal reabsorption, and regulation of renin release (41) responsible for sodium balance and fluid volume. Although, PGE2 has been reported to inhibit chloride reabsorption in the ascending limb of Henle (42), chronic sodium deprivation was found to increase COX-2 levels in the region of the macula densa. COX-2 generated prostanoids are important mediators of renin production and tubulo-glomerular feedback. The details of interactions between the COX-1 and COX-2 mediated systems in the kidney are unclear. Mapping of PG receptors in the kidney (6) does show differential locations of receptors specific for different PGs, indicating that differential synthesis of specific types of prostaglandins may be responsible for separating the effects of COX-1 and COX-2. In addition to the multiple roles played by PGs in the adult kidney, COX-2 null mice show severe disruption of kidney development (43, 44). The localization and level of COX-2 expression in the human kidney is currently unknown, but this information will be essential in evaluating the role of COX-2 in human kidney function. NSAIDs are known to have multiple effects on kidney function, and specific COX-2 inhibitors should be useful in dissecting the role of PGs generated from the COX-2 pathway in normal renal physiology.

Nerve and Brain Physiology

COX-2 seems to have some role in regulating brain function (45). PGs have long been known as mediators of fever, inflammatory reactions in neural tissue and more recently in brain function. Each of these processes involves induction of PG biosynthesis and COX-2 especially plays an important role. While NSAIDs are commonly used to control fever, the actual mechanism of fever induction has only recently been described. Intraperitoneal injection with lipopolysaccharide (LPS) causes a marked fever response in rats. In an elegant dissection of molecular and tissue interactions, Cao and colleagues have shown how COX-2 induction in brain endothelial cells temporally correlates the fever response (45, 46). This leads to the synthesis of PGs, which then act on temperature sensing neurons in the preoptic area. In turn, COX-2 inhibition by an isoform-specific NSAID can effectively block fever (47). Communication between local inflammatory sites and the brain endothelium is mediated by cytokines such as IL-1, which can directly induce COX-2 expression in these cells (48). These investigators have also shown induction of COX-2 expression in other parts of the brain, but these areas are not directly associated with the fever pathway. A separate inflammatory pathway is one mediated by microglial cells, tissue specific macrophage that lies dormant until needed for defense or tissue remodeling (49). The microglial cell does not show induction of COX-2 in response to cytokines, in strong contrast with other inflammatory cells. In the microglial COX-2 response is limited to direct LPS exposure by bacterial infection of the brain. Thus, the microglial defensive response is segregated from systemic inflammation by its limited repertoire of inducers. This segregation is important because COX-2 also plays a central role in neural development and adaptation. In the earlier stages of brain development, neural genes and proteins are developmentally induced that play an important role in the maturation process. During later stages of maturation, environmental influences as represented by neural responses and synaptic activity, play an increasingly important role in determining brain structure. It is in these final stages of development and brain modeling that COX-2 becomes active in a manner that coincides with the imprinting of environmental influences (50). COX-2 remains an important modulator of neural response throughout adult life. Seizures and N-methyl-D-aspartate mediated activity increase COX-2 levels (51). The sites of induction being the postsynaptic dendritic arborizations (52) of specific excitatory neurons located in the major processing centers of the brain. The actual role of COX-2 and PGs in these sites is to be understood. However the association of COX-2 induction and neural degeneration after glutamate stimulation (53), seizures, and spreading depression waves (54) suggest that COX-2 may play more of a role in the selective loss of neural connections than in their formation.

Role of COX isoforms in Alzheimer’s disease (AD)

AD is a neurodegenerative disorder of unknown etiology that accounts for two-thirds of all dementia in the elderly. Although the inciting event responsible for initiation of the disease remains unclear, pathological studies of early to late stage AD demonstrate prominent neuronal and synaptic loss in concert with amyloid deposition and astrocytic and microglial activation. In AD, neuronal COX-2 levels have been found to be either elevated (55, 56) or unchanged (57). Recent studies suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a significantly lower risk of developing AD (58, 59), raising the possibility that in normal aging populations, inhibition of COX activity may be protective against the development of AD. However, the precise pharmacological actions of anti-inflammatory drugs in the brain are still unclear. Several studies are attempting to identify a role for COX in the etiology of AD. Cytokines such as IL-1 or IL-6, as well as acute-phase proteins such as 1-antichymotrypsin (ACT), participate in the etiopathology of AD. Tepoxalin, a novel NSAID, markedly inhibited IL-1 induced IL-6 and ACT synthesis in astrocytes (60). Lipopolysaccharide stimulated microglial cells treated with tepoxalin also exhibited decreased synthesis of IL-1 and IL-6 (59). This effect was mediated through inhibition of NF-B via decreased IB degradation. NF- is known to activate COX-2 expression under some circumstances. The amyloid stimulated secretion of proinflammatory products by microglia and monocytes, mediating neurotoxicity and astrocyte activation, was also inhibited by NSAIDs, reportedly through PPAR activation (61).Recognition of COX-2’s key role in inflammation led to the hypothesis that it may represent a primary target for NSAIDs in AD, consistent with inflammatory processes occurring in AD brain (62, 63).

Elevated CSF PGE2 levels are observed in patients with probable AD (64). COX-2 was elevated in the hippocampal pyramidal layer in sporadic AD and was correlated with amyloid plaque density (65). In vitro studies using COX-2 over expressing neurons derived from transgenic mice suggest that elevation of COX-2 may potentiate A-beta mediated oxidative stress (65). Further analyses of 54 post mortem brain specimens from patients with normal or impaired cognitive status suggested that neuronal COX-2 expression in subsets of hippocampal pyramidal neurons may be a marker of progression of dementia in early AD (66). IL-1 and synthetic amyloid peptides induced COX-2 expression and PGE2 release in the human neuroblastoma cell line SK-NSH (67, 68). In human breast cancer cells (69), neuroblastoma cells also exhibit increased COX-2 expression mediated by p38 mitogen activated protein kinase (MAPK), suggesting p38 MAPK as a potential therapeutic target in AD (68). However, COX-1 and COX-2 may be involved in different cellular processes in the pathogenesis of AD, as indicated by their different distribution profile. An overall increase of COX-1 expression in AD has also been suggested COX-1 expression was detected in microglial cells, whereas COX-2 expression was found in neuronal cells (70). In AD brains, COX-1positive microglial cells were primarily associated with the amyloid plaques, and AD fusiform cortex exhibited increased density of COX-1 immunopositive microglia (70, 71). Furthermore, more COX-2 positive neurons were detected in AD brains than in control brains (70). Although in vitro studies use astrocytes to investigate the role of COX in AD, no COX expression was detected in astrocytes in vivo. Therefore, COX-1 could also contribute to central nervous system pathology, which brings up the issue of whether non selective inhibitors would be more effective. The possible implication of COX-1 in AD is further substantiated by the Alzheimer’s disease Cooperative Study (ADCS) (72). A multicenter clinical trial found that a repressor of COX-2 expression, prednisone neither prevented nor accelerated cognitive decline in AD, although interpretation of these data is complex because glucocorticoids are fairly nonspecific and affect many other pathways. Nevertheless, the ADCS has initiated a trial to compare a nonselective NSAID and a selective COX-2 inhibitor for effectiveness in slowing the rate of cognitive decline in AD. Indomethacin showed promising results in a pilot clinical trial (73). Whether COX-2 inhibitors will be more effective is uncertain, since the enzyme is constitutively expressed in neurons and may play some role in normal brain function (74). Animal experiments suggest that COX-2 may be responsible for the regulation of adaptive functions associated with normal neurons and protective functions associated with stressed neurons. Other mechanisms for NSAID neuroprotective potency unrelated to their ability to inhibit COX-1 or COX-2, such as inhibition of monocyte cytotoxicity, have been suggested based on in vitro neurotoxicity assays (75). The antithrombotic activity of PGs may also be important for protection against AD. De la Torre (76) hypothesizes that AD is caused by the development of tortuous and flow-impeded capillaries in the brain. This would presumably promote intravascular coagulation, leading to ischemic damage in the brain that could promote the development of AD. Platelets contain both APP and A- which may contribute to the perivascular amyloid deposition seen in AD. Protein kinase C (PKC) in human platelets is involved in the secretory cleavage of APP, whereas COX plays only a minor role in this process (77). The precise role of the COX isoenzymes in AD is not clear, but the use of NSAIDs that inhibit both COX-1 and COX-2 activity appears to be beneficial. Non-selective NSAIDs can reduce inflammation associated with activation of microglia, but they seem ineffective in reversing the degenerative process in AD. A recent study suggests that naproxen, ibuprofen, and aspirin may reduce the risk of Alzheimer's disease. Nevertheless, the effects of NSAIDs are likely to be mediated through a combination of mechanisms. Although reduced microglial or monocyte activation has been shown to be effective in various cell culture and animal models, clinical studies have yet to be performed. Mechanistic studies already under way will provide insight and directions for further development.

Role of COX isoforms in Parkinson’s disease (PD)

PD is other common neurodegenerative disease which is characterized by motor abnormalities causing tremors, muscle stiffness, paucity of voluntary movements, and postural instability (78). Its main neuropathlogical feature is the loss of the nigrostriatal dopamine containing neurons, whose cell bodies are in the substantia nigra pars compacta (SNpc) and nerve terminals in the striatum (79). Except for a handful of inherited cases related to known gene defects, PD is a sporadic condition of unknown pathogenesis (78). Epidemiological studies suggest that inflammation increases the risk of developing a neurodegenerative condition such as AD (80). Hence, inflammatory processes associated with increased expression of COX-2 and elevated levels of prostaglandin E2 (PGE2) have been implicated in the cascade of deleterious events leading to neurodegeneration in PD associated pathological settings (81–83). COX in general convert arachidonic acid to PGH2, the precursor of PGE2 and several other prostanoids, and exists in eukaryotic cells in two main isoforms: COX-1, which is constitutively expressed in many cell types; and COX-2, which is normally not present in most cells, but whose expression can readily be induced in inflamed tissues in PD also (84). Although both isoforms synthesize PGH2, COX-1 is primarily involved in the production of prostanoids relevant to physiological processes, whereas COX-2 is mainly responsible for the production of prostanoids linked to pathological events (84). COX-2 expression is induced specifically within SNpc dopaminergic neurons in postmortem PD specimens and in the 1-methyl-4-phenyl-1,2,3,6- tertrahydropyridine (MPTP) mouse model of PD during the destruction of the nigrostriatal pathway and COX-2 induction occurs through a JNKyc-Jun dependent mechanism and that COX-2 ablation and inhibition attenuate MPTP induced nigrostriatal dopaminergic neurodegeneration, not by curtailing inflammation, but possibly by mitigating oxidative damage which is evident of COX-2 involvement in the pathogenesis of PD and suggest a potential mechanism for the selectivity of neuronal loss in this disease (Figure 2). Collective data thus provide evidence for COX-2 up regulation in MPTP and PD and support a significant role for COX-2 in both the mechanism and the specificity of MPTP and PD induced SNpc dopaminergic neuronal death. The present studies suggest that inhibition of COX-2 may be a valuable target for the development of new therapies for slowing the progression of the neurodegenerative process during PD.

Figure 3
Figure 2. Higher COX-2 [removed]blue stain) in neurons from

Parkinson’s disease

Increasing evidence suggests that neuroinflammation is an active process in PD that contributes to ongoing neurodegeneration. PD brains and experimental PD models show elevated cytokine levels and up regulation of inflammation associated factors as COX-2 and inducible nitric oxide oxidase. Antiinflammatory treatment reduced neuronal degeneration in experimental models.

Role of COX isoforms in maintenance of Gastrointestinal integrity

The intestinal epithelium is a tissue that undergoes constant regeneration in response to both insult and normal use. The use of NSAIDs causes irritation and ulceration of the stomach lining of the gastrointestinal tract (85). Under these circumstances, COX-1 appears to play a major role in maintaining proper glandular architecture. Gastrointestinal epithelium is also the target of numerous infectious and parasitic organisms. In response to infection or invasion, COX-2 expression is induced in epithelial cells (86), which leads to increased PG production. The PGs then stimulate chloride and fluid secretion from the mucosa that flush bacteria from the intestine. In addition, COX-2 is expressed during inflammation and wound healing, and in animal models, treatment with COX-2 inhibitors can exacerbate inflammation and inhibit healing. Nevertheless, COX-2 selective inhibitors appear to be associated with less gastrointestinal damage than conventional NSAIDs (87). Many of the diverse roles of PGs in the intestine have been revealed by studying the effects of indomethacin or other NSAIDs. Giannella et al. (88) have found that indomethacin could effectively suppress the rapid intestinal fluid secretion accompanying Salmonella infection of Rhesus monkeys. More recently, Eckmann et al. (89) have shown that Salmonella infection of cultured intestinal epithelial cells gives rise to a rapid induction of COX-2, and associated rise in PGs, and increase in chloride secretion. With such response of infected cells, uninfected cells also acquired the property of enhanced fluid secretion, demonstrating the paracrine nature of the PG response.

Role of COX isoforms in Ovaries and Uterus

The uterus epithelium is a tissue that undergoes constant regeneration in response to both insult and indomethacin as a treatment for premature labor with dramatic results. Out of 50 women, 80% experienced cessation of uterine contractions. However, five infants from the treated mothers died because of premature closure of the ductus arteriosus, a circulatory shunt in the fetus that allows the output of the left ventricle to bypass the fetal lungs, which is maintained by PGs (90). Prenatal indomethacin is sufficient to block PG production leading to premature duct closure and disruption of fetal circulation (90). Ovulation, the process by which oocytes are released from the pre ovulatory follicle in the ovary is accompanied by induction of prostaglandin synthesis as a consequence of the LH surge. This marked response led to the first observation of COX-2 induction during a normal physiological event (91). One of many molecular events associated with ovulation (92), the induction of COX-2 is necessary for the successful rupture of the follicle, probably mediating directly the generation or activation of proteolytic enzymes necessary for this process (93). Induction of COX-2 can be modulated by the gonadotropins LH and FSH, and by TGF-a, IL-1, or other cellular signaling pathways (94). After fertilization, COX-2 again plays a role, this time during implantation of the embryo in the uterine endometrium. During the pre-implantation period, uterine COX-1 (95) and the PGE2 receptors, EP1, EP3, and EP4 (96), may modulate preparation of the uterus for interaction with the embryo, and COX-2 (95) and the EP2 receptor (97) appear to mediate the embryo uterine interactions during implantation. COX-2 null mice show multiple failures in reproductive function, including ovulation, fertilization, implantation, and decidualization, underscoring the multiple roles of PGs during these processes (98). Finally, at the completion of pregnancy, PGs again act in the ovary and uterus to help mediate the delivery process. As mentioned above, PGs have long been known to stimulate uterine contraction. In mice, the production of PGF2a by the fetal and/or uterine tissues signals the ovary to induce luteolysis (99), leading to a decline in maternal progesterone and the induction of oxytocin receptors in the myometrium. This induction in turn increases the myometrial response to oxytocin and brings on parturition. One of the earliest noted sites of PG accumulation was amniotic fluid (100), and one of the first known biological responses to a prostaglandin was the rhythmic contraction of the uterine myometrium. These associations with pregnancy and labor led to the recognition of PGs as a major effector in induction of labor. Indeed, administered indomethacin as a treatment for premature labor with dramatic results (101).

COX isoforms and Bone

PGs were initially characterized by stimulating bone resorption in culture, human and animal responses to PGs often include stimulation of bone formation (102). Collagen synthesis by osteoblasts can be both stimulated (103) or inhibited by PGs. Mechanical stress on bone cells leads to an increase in PG synthesis, suggesting that immobilization would be characterized by low PG levels (104). Nevertheless, immobilization is associated with PG mediated bone loss, an effect that is slowed by NSAIDs. PGs act on the modeling of bone in several ways. They stimulate the differentiation of precursors of both the bone resorbing cells (osteoclasts) and the bone forming cells (osteoblasts), they stimulate bone resorption in vitro, and they stimulate bone growth when given exogenously in vivo (105). While little is known of how PG synthesis affects the balance between bone loss and formation, COX-2 induction in osteoblasts is reported to be essential to the acute stress response in a bone remodeling system (106). Bone loss is associated with inflammation in periodontal disease (107) and NSAIDs can slow this process (108). Cytokines associated with inflammation, including IL-1b and IL-6 (109) have been found to induce both COX-2 and increase PG production when added to bone marrow cells in culture. In response, osteoclasts are induced to differentiate from their stem cell precursors. Osteoblasts and marrow stromal cells are the site of COX-2 induction and are further activated by the increased production of PGs. Other cytokines, for example IL-4 and IL-13 appear to suppress this response (110). Other inducers of COX-2 include parathyroid hormone (111), an important regulator of calcium metabolism, vibrational forces (112) and pulsating fluid flow (104), both of which are thought to model physical forces associated with mechanical stress on bone. Thus, it appears that stimuli that lead to both breakdown and building of bone use the same basic pathways to activate the bone remodeling system and that in bone PGs are responsible for ensuring that this resorption and formation occur coordinately, preventing an imbalance between these two processes.

Role of COX isoforms at Joints and in Arthritis

Although the importance of COX activity in the production of PGs has been known since long (113), the inducibility of this activity and the central role of this induction in the amplification of inflammation have been fully appreciated only recently (114). Evidence provided by animal models of inflammatory arthritis strongly suggests that increased expression of COX-2 is responsible for increased PG production seen in inflamed joint tissues (115). COX-2 induction has been observed in both human osteoarthritis affected cartilage (116) as well as in synovial tissue taken from patients afflicted with rheumatoid arthritis (117). Cell culture experiments utilizing primary cells derived from human synovial tissue or cell types (monocytes) important in inflammatory processes have been critical to an understanding of factors involved in modulating this induction. The pro-inflammatory agents IL-1, TNF-a, and LPS, as well as the growth factors TGF-b, EGF, PDGF, and FGF, have all been shown to induce COX-2 expression in this system. On the other hand, the antiinflammatory cytokines IL-4 and IL-13, as well as the immunosuppressive glucocorticoids, were shown to decrease COX-2 levels. Although the synovial tissues of patients with osteoarthritis express lesser amounts of COX-2, primary in vitro cultures of human osteoarthritis affected cartilage spontaneously express large amounts of COX-2 and PGs (116). Nitric oxide, another important inflammatory modulator, has been shown to regulate PG production in osteoarthritic cartilage, though not in synovial cells. Whether this modulation attenuates or enhances COX activity remains controversial (116, 118). The rapid expansion of knowledge about the role of COX-2 in inflammation led to drug screens attempting to identify antiinflammatory agents selective for COX-2 as well as to the rational design of highly selective COX-2 inhibitors (119). The availability of these COX-2 inhibitors has now allowed for the design of studies that could directly determine the importance of COX-2 in inflammatory disease. COX- 2 is reported to be central to the inflammatory process and COX-2 inhibition is sufficient to achieve the same therapeutic endpoints found with less specific inhibitors that also target COX-1(120).

Role of COX isoforms in Pain

Local tissue injury and inflammatory diseases like osteoarthritis are associated with increased PGs, and pain receptors are known to be sensitized to lower levels of stimulus by PGs (121). Thus, the action of COX at the site of injury or inflammation is hyperalgesic, and the pain relieving action of NSAIDs at the local site is easily explained by this mechanism. In addition, PGs are thought to act in the spinal cord to facilitate the transmission of pain responses, though there is little known about how they might do this (122). NSAIDs can also act at these central sites (123–125). COX-2 is induced in both local and central sites (126), and the question of whether COX-2 mediates pain reception or transmission is being investigated, primarily through the use of COX-2 specific NSAIDs. Intrathecal injection of both the COX-2 specific inhibitor NS-398 and the nonspecific NSAID indomethacin suppressed a formalin mediated pain response (which measures a central response), but neither suppressed a high temperature induced local pain response (122). In contrast, systematically administered meloxicam, an NSAID more specific for COX-2 than COX-1, suppressed the inflammatory pain response locally (127) without affecting central pain transmission. In neither of these studies was the drug introduced into both sites to allow an internal comparison, but together they show that COX-2 can act both locally and centrally to mediate pain. In fact, the COX-2 specific inhibitor Celecoxib was shown in short term human studies to effectively suppress the pain associated with dental work, osteoarthritis, or rheumatoid arthritis without causing any significant gastro duodenal lesions (127, 128).

Role of COX isoforms in Cancer

Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received considerable attention due to its role in human cancers. Observational and randomized controlled studies in many different population cohorts and settings have demonstrated protective effects of nonsteroidal anti-inflammatory drugs for colorectal cancers (CRCs). COX-2, the inducible isoform of COX, is over-expressed in early and advanced CRC tissues. Experimental studies have identified important mechanisms and pathways by which COX-2 plays an important role in carcinogenesis. Selective COX-2 inhibitors have been approved for use as an adjunctive therapy for patients with familial polyposis. The role of COX-2 inhibitors is currently being evaluated for use in wider populations. The connection between inflammation and cancer was proposed long ago by Rudolph Virchow. The cancerous tissue also contains the cells and factors responsible for the features of the body's inflammatory response. Therefore, Virchow hypothesized that cancer begins at sites of chronic inflammation. Since that time the scientific community disavowed the idea that infection could also cause harm. The NSAIDs act by blocking COX-1 and COX-2, thus inhibiting the conversion of arachidonic acid to thromboxane and prostaglandins (129). Whilst COX-1 is expressed in platelets and the gastric mucosa, COX-2 is specifically induced in sites of inflammation and neoplasia. Over expression of COX-2 was found to stimulate angiogenesis in tumors (130). Angiogenesis is an essential step in the transition of in situ cancers to invasive forms (131,132) and in the development of distant metastasis (133–135). COX-2 stimulates angiogenesis via multiple mechanisms.

The current understanding of the role of cyclooxygenase in cancer can be concluded as (i) promotion of the production of vascular endothelial growth factor, a potent angiogenic growth factor, by increasing its mRNA transcription (136, 137); (ii) production of thromboxane A2, prostaglandin E2 (PGE2) and prostacycline, products of arachidonic acid which are direct stimulants of endothelial cells (138–140); (iii) up regulation of matrix metallo-proteinases, which are endopeptidases essential for tumour and vascular cell invasion (141, 142) and (iv) inhibition of the production of interleukin-12, a potent antiangiogenic cytokine (143, 144). Another pro-cancerous effect of the over expression of COX-2 is the increased resistance to apoptosis (145). This resistance is caused by the increased production of Bcl-2, an antiapoptotic protein, in response to high levels of PGE2 – a product of COX-2 (146, 147). Another pro survival effect of COX-2 is the activation of the Akt system which is essential for vascular endothelial cell survival (1480. The increased production of prostaglandins by COX-2 can cause local immune suppression by decreasing the activity of both lymphocytes and natural killer cells and inhibition of the production of TNF- that can alter the antitumour immune response (149,150). In several types of cancer, over expression of COX- 2 is correlated with advanced disease and poor prognosis (151, 152). COX-2 inhibitors were found both in vitro and in vivo to be antiangiogenic agents and to induce apoptosis (130, 153). These studies have provided further evidence for the role of COX-2 in carcinogenesis. Some studies have suggested that their anticancer effect may also be through COX-2 independent mechanisms, such as by increasing the level of endostatin an endogenous angiogenesis inhibitor (154) and by interference with DNA binding of transcription factors (155). COX-2 is induced by procarcinogens found in tobacco smoke and in turn, its peroxidase activity converts these chemicals into highly reactive mutagens that bind to DNA (156). This data has kindled interest in the possible effects of NSAIDs as anticancer agents, and also encouraged many studies on the preventive roles COX-2 selective and non-selective NSAIDs in many types of cancers.

Role of COX-2 in Atherosclerosis

COX is the rate limiting enzyme catalyzing the conversion of arachidonic acid into prostanoids, the lipid mediators critically implicated in a variety of physiological and path physiological processes, including inflammation, vascular and renal homeostasis, and immune responses. In the setting of acute ischemic syndromes it has been recognized that COX pathway plays an important role. The function of platelet COX-1 in acute ischemic diseases is firmly established, but the role of COX-2 in atherothrombosis remains controversial. The complex role of COX-2 in this setting is also confirmed by the unexpected cardiovascular side effects of long-term treatment with COX-2 inhibitors (157)

The COX-2 influences the construction of atheromatous tissue. The lesion involves three cell types; endothelial, monocytic/macrophage, and vascular smooth muscle cells. Disruption of the endothelial cell barrier between circulating blood and tissue, monocyte/macrophage sequestration at these sites with elaboration of inflammatory cytokines, and the transmigration and uncontrolled proliferation of vascular smooth muscle cells typify the initial phase of the atherosclerotic process. COX-2 expression has been found in each of these cell types in animal models as well as in human atherosclerotic tissue (158–160). Similarly, COX-2 can be induced in these cells by many, of the same proinflammatory mediators implicated in the development of atherosclerosis. Such mediators include tumour necrosis factor (TNF), interleukin-1 (IL-1), interferon- , free radicals, endotoxin, platelet-derived growth factor, hypoxia, and sheer stress as recently reviewed (160). The presence of COX-2 in cells which comprise the atheromatous lesion as well as its inducibility by mediators of atherogenesis are in keeping with experimental and clinical data showing that prostaglandin production is increased in atherosclerosis; just as it is in other inflammatory conditions (160,161).

The histological findings show COX-2 expression is found in human atheromatous plaque lesions in diseased coronary arteries resected at the time of surgical revascularization, but not in normal coronary arteries (158, 159). Furthermore, COX-2 expression co-localizes with inducible nitric oxide synthase (iNOS), suggesting an interaction between the two inflammatory mediators. Lastly, augmented COX-2 expression is present in diseased, transplanted coronary arteries to the same extent as that found in diseased native coronary arteries (159).

Accumulation of low-density lipoprotein (LDL) in the sub endothelial region of the vascular wall is a primary event in the initiation of atherosclerotic injury. Monocytes attracted to these areas of accumulated LDL by increased expression of adhesion molecules on endothelial cell membranes, aggregate on the surface of the lumen and subsequently transmigrate into the intimal layer. Here they differentiate into macrophages which scavenge lipoproteins, ultimately forming foam cells. LDL, however, is first oxidatively modified which facilitates its uptake by the macrophage (162). Oxidized LDL (oxLDL) accelerates the formation of foam cells that contribute their lipid contents to fatty streak formation, the histological hallmark of the initial stage of atherosclerosis. Experimentally, the ability of oxLDL to activate a macrophage is not only dependent on oxidation of either the protein moiety or lipid moiety of the LDL molecule, but also requires fully differentiated macrophages derived from monocytes (163). The relationship between COX-2 and oxLDL is not straightforward. Activated macrophages produce a variety of inflammatory mediators, including prostaglandins. Thus, increased COX-2 activity would be expected in oxidatively stressed macrophages given its inducible nature. In animal models, however, macrophages exposed to oxidized lipoproteins decrease their prostaglandin production (PGE2 and PGI2) when stimulated by inflammatory cytokines such as lipopolysaccharide (LPS) (164). As such, cholesterol rich macrophages and foam cells appear to have an impaired or reduced inflammatory response, rather than an augmented one, following oxLDL exposure (165). Recently, Eligini et al. (166) reported that oxLDL inhibited LPS induced COX-2 expression in human macrophages.

The pathophysiological significance of oxLDL's ability to down regulate COX-2, specifically, and to diminish macrophage responsiveness to inflammatory stimuli, globally remains unclear. One argument highlights the negative feedback exerted on macrophage colony stimulating factor (M-CSF) by PGE2 and PGI2 (167). Enhanced M-CSF secretion by monocytes could foster proliferation and accumulation of macrophages in areas of atheroma formation, potentiating the atherosclerotic process. Another argument contends that normal resolution of inflammatory processes requires intact and robust cellular responses to such stimuli, ‘effective clean-up’ in essence. Blunted inflammatory responses by macrophages exposed to oxLDL, early in the development of atheromatous lesions, could limit tissue repair and result in a low grade state of chronic inflammatory injury which is unable to repair itself. Pharmacological intervention with selective COX-2 inhibitors may help to delineate the relationship between oxLDL, COX-2, and the activated macrophage. Another lipoprotein, high-density lipoprotein or HDL, exerts an ‘antiatherogenic’ or protective effect on the cardiovascular system. A strong inverse correlation exists between levels of HDL and the frequency as well as mortality of atherosclerotic disease (168). Functionally, HDL is known to remove excess cholesterol from the circulation and inhibit oxidation of LDL. The latter function is accomplished by paraoxonase; an esterase that degrades oxidized phospholipids and which uses HDL as its carrier protein (169). What is not clear is whether HDL's angioprotective effect is attributable to these or to other unrelated functions. Cockerill et al. have reported on the inhibitory effect of HDL on cytokine induced adhesion molecule expression by human endothelial cells (170). Based upon previous observations that HDL stimulates endothelial cell PGI2 synthesis (171), these investigators also reported that HDL can synergistically increase COX-2 expression in human endothelial cells following cytokine stimulation with either IL-1ß or TNF . The synergistic increase in COX-2 protein is mirrored by increased PGI2 production in these cytokine stimulated cells (172). Although HDL clearly has opposing effects on two cytokine stimulated responses by human endothelium, the results may be additive. On one hand, an increase in PGI2, mediated by a HDL induced increase in COX-2 expression, serves to inhibit platelet aggregation, cholesterol accumulation, and vascular smooth muscle cell proliferation/contraction and thus may be vasoprotective. Concurrently, decreased expression of adhesion molecules on cytokine-induced endothelial cell membranes may also be consistent with an antiatherogenic effect of HDL.

PGI2 is a metabolite of arachidonic acid and the major prostaglandin produced by endothelial cells. As mentioned earlier, PGI2 is a potent inhibitor of leukocyte activation and adhesion, platelet aggregation, and vascular smooth muscle cell proliferation, migration and contraction. Its role in vivo, however, has remained unclear. Recently, a knockout mouse deficient in the PGI2 receptor IP, has demonstrated an antithrombotic as well as antiinflammatory role for PGI2 (173). It is also well established that PGI2 excretion is increased in patients with ‘activated platelet’ conditions such as unstable atherosclerotic disease as well as following vascular interventional procedures (161). On one hand, it would not be unreasonable to predict a facilitative role for COX-2 in these conditions of increased PGI2 production, given its inducible nature and the fact that COX-2 is responsible for the majority of PGI2 produced in the body (174). On the other hand, nonselective NSAID therapy (sulindac and indomethacin) inhibits intimal proliferation and prevents or slows vascular changes in atherosclerosis prone mice while aspirin and nimesulide (a selective COX-2 inhibitor) do not (175).

Clinically, a question arises regarding the lack of inhibition by selective COX-2 inhibitors of thromboxane (TBX), a COX-1 mediated prostaglandin, produced primarily by platelets. Given TBX's procoagulant and vasoconstricting effects, long term therapy with COX-2 inhibitors may create a state of chronic, ‘unopposed’ TBX activity with potentially deleterious cardiovascular outcomes. In the VIGOR trial, for example, over 8000 patients with rheumatoid arthritis were randomized to receive either naproxen (500 mg po bid) or rofecoxib (50 mg po q day) for 12 months (176). Aspirin therapy was excluded in all subjects since the mucosa of the GI tract was being evaluated. Although rofecoxib demonstrated a marked gastro protective effect, a significantly increased incidence of myocardial infarction occurred in the rofecoxib treated group. A large percentage of these adverse events occurred in a small subset of patients who were at risk for myocardial infarction and should have been receiving aspirin therapy but were unaware of their risk factors at the time of randomization. These results have been attributed to the lack of antiplatelet activity demonstrated by selective COX-2 inhibitors. As noted recently, selective COX-2 inhibition may offer gastro protection but not cardio protection (177). COX regulates the production of eicosanoids, which modulate physiologic processes in the vessel wall contributing to atherosclerosis and thrombosis, including platelet aggregation, control of vascular tone, and the local inflammatory response. Cyclooxygenase-1 mediates production of platelet thromboxane A2, a potent vasoconstrictor and platelet agonist, whereas both COX 1 and 2 contribute to production of endothelial prostacyclin, a vasodilator that inhibits platelet activation. Concerns have been raised that COX-2 inhibitors may increase thrombotic cardiovascular events by disturbing the balance between platelet thromboxane A2 and endothelial prostacyclin, but this controversial issue will only be resolved by prospective clinical trials. Because COX-2 is upregulated in activated monocyte/macrophages, which play a key role in the pathogenesis of atherosclerosis, it is recently tested hypothesis that pharmacological inhibition of COX-2 in LDL receptor deficient mice would reduce early atherosclerosis. After 6 weeks on a Western-type diet, male LDL receptor deficient mice treated with either rofecoxib (a selective COX-2 inhibitor) or indomethacin (a non-selective COX inhibitor) had significant reductions in atherosclerosis when compared with control mice. Also, LDL-receptor deficient mice null for macrophage COX-2 were generated by fetal liver cell transplantation and developed significantly less atherosclerosis than control LDL-receptor deficient mice transplanted with fetal liver cells wild type for COX-2, providing genetic evidence in support of a pro atherogenic role for macrophage COX-2 expression. These results support the potential of antiinflammatory approaches for the prevention of atherosclerosis and identify cyclooxygenase-2 as a target for intervention (178).

Conclusion

This review highlights the role of COX isoforms in many physiological systems. The precise mechanisms by which this biosynthetic pathway can mediate such diverse functions are still being understood and will likely continue until researchers fully characterize the biology of the various PG synthases and receptors downstream of COX. Nevertheless, identifying an inducible COX was a major breakthrough in this area. What evolved from this discovery was a paradigm in which one isoform, COX-1, was mainly responsible for the biosynthesis of PGs involved in homeostatic regulation, while the second isoform, COX-2, was primarily involved in producing PGs in response to a wide spectrum of environmental insults and internal stimuli. Such a mechanism appears to explain, at least in part, both the therapeutic and toxic effects of NSAIDs in humans. The major side effects of NSAIDs, gastro duodenal erosion and disruption of normal renal function, appear to be caused by the inhibition of COX- 1, while the antiinflammatory and analgesic activity of these drugs rests largely on their ability to inhibit COX-2. Investigations into the role of COX-2 in disease have suggested that chronic activation of this enzyme may be pathological in the colon, where there is strong evidence to suggest that inhibition of COX-2 can limit the progression of colorectal cancer. Thus, a little more than a century after the discovery of aspirin, the potential clinical indications for NSAID use appear to be widening from their original purpose as analgesic agents. COX-3 is considered a new and important lead in the generation of anti-inflammatory and analgesic agents. However, a frame shift caused by complete retention of intron 1 in the human sequence questions its relevance to human pathophysiology Ongoing studies to more clearly delineate the role of each COX isoform will be crucial in defining the use of these drugs in the next century. COX-2 is now considered as a viable target for chemotherapy, especially since selective COX-2 inhibitors have improved safety profiles compared with nonselective NSAIDs and are much less toxic than most chemotherapeutic agents. There is increasing evidence for the involvement of COXs in the development and progression of cancer, Alzheimer’s disease, Parkinson’s disease and other pathophysiological states. Development of therapeutic and diagnostic tools to treat these diseases is being actively investigated. Moreover, variants of cyclooxygenase derived from alternative splicing have been reported. Elucidation of the roles played by these variants could provide greater insight into the roles of COXs in health and disease.

References

1. Mead JF., Alfin-Slater RB., Howton DR., and Popjak G. Prostaglandins, thromboxanes and prostacyclin. In Lipids: Chemistry, Biochemistry, and Nutrition. 1986; 149–216.
2. Forman BM., Chen J., and Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann. N.Y. Acad. Sci. 1996; 804: 266–275.
3. Herschman HR., Xie W., and Reddy S. The regulation and role of the inducible prostaglandin synthase. Bioessays. 1995; 17: 1031–1037
4. Simon LS. Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr. Opin. Rheum. 1996; 8: 169–175
5. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Diseases. Colon. Rectum. 1995; 38: 1311–1321
6. Murray MD and Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharm. Toxicol. 1993; 32: 435–465
7. Raz A., Wyche A., Siegel N and Needleman P. Regulation of fibroblast Cyclooxygenase synthesis by interleukin-1. J. Biol. Chem. 1988; 263: 3022–3028
8. Reed DW., Bradshaw WS., Xie W., and Simmons DL. In
vivo and in vitro expression of a non-mammalian cyclooxygenase-1. Prostaglandins. 1996; 52: 269–284
9. Smith W., Garavito R and DeWitt D. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996; 271: 33157–33160
10. Kutchera W., Jones DA., Matsunami N., Groden J., Mc-Intyre TM., Zimmerman GA., White RL and Prescott SM. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl.
Acad. Sci. USA 1996; 93: 4816–4820
11. Reddy ST and Herschman HR. Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1 . J. Biol. Chem.1996; 271: 186–191.
12. Williams CS and Dubois R. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. 1996; 270: 393– 400.
13. Hoff T., DeWitt D., Kaever V., Resch K., and Goppelt-Struebe, M. Differentiation associated expression of prostaglandin G/H synthase in monocytic cells. FEBS Lett. 1993; 320: 38–42
14. Murakami M., Matsumoto, R., Austen KF., and Arm JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J. Biol.
Chem. 1994; 269: 22269–22275.
15. Ueda N., Yamashita R., Yamamoto S and Ishimura K. Induction of Cyclooxygenase-1 in a human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochim. Biophys. Acta. 1997; 1344: 103–110
16. Smith CJ., Morrow JD., Roberts LJ., and Marnett LJ. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase- 1 (COX-1). Biochem. Biophys. Res. Commun. 1993;192: 787–793.
17. Herschman HR. Prostaglandin synthase 2. Biochim. Biophys. Acta. 1996;1299: 125–140
18. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS and Simmons DL COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad
Sci. U S A 2002; 99: 13926-13931
19. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheum. 1997; 24:15–19.
20. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J. Clin. Pharmacol. 1995; 35: 209–219
21. Palmer BF and Henrich WL. Clinical acute renal failure with nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 1995; 15:214–227
22. Zambraski EJ. The effects of nonsteroidal anti-inflammatory drugs on renal function: experimental studies in animals. Semin. Nephrol.1995;15: 205– 213
23. Trevethick MA., Oakley I., Clayton NM., and Strong P. Non-steroidal anti-inflammatory drug-induced gastric damage in experimental animals: underlying pathological mechanisms. Gen. Pharmacol. 1995; 26: 1455–1459
24. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997; 112: 1000–1016
25. Reingold DF., Watters K, Holberg S et al. Differential biosynthesis of prostaglandins by hydronephrotic rabbit and cat kidneys. J Pharmacol Exp Ther. 1981; 216: 510-515
26. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin. Arth. Rheum. 1996; 26: 435– 436
27. DeWitt DL., Meade EA and Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am. J. Med. 1993; 95: 40–44.
28. Harris RC., McKanna JA., Akai Y., Jacobson HR., DuBois RN and Breyer MD. Cyclooxygenase-2 is associated with the macula densa in rat kidney and increases with salt restriction. J. Clin. Invest.1994; 94: 2504–2510
29. Guan Y., Chang M., Cho W., Zhang Y., Redha R., Davis L., Chang, S., Dubois, R. N., Hao, C. M and Breyer, M. Cloning, expression, and regulation of Rabbit Cyclooxygenase-2 in renal medullary interstitial cells. Am. J. Physiol. 1997; 273:18–26
30. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis.2000; 31: S202–210.
31. Chandrasekharan NV., Dai H., Roos KL., Evanson NK., Tomsik J., Elton TS., Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. PNAS. 2002; 99: 13926-13931.
32. Snipes JA., Kis B., Shelness GS., Hewett JA and Busija DW, Cloning and Characterization of Cyclooxygenase-1b (putative COX-3) in Rat. J Pharmacol Exp
Ther. 2005; 315: 1298–305.
33. Davies NM., Good RL., Roupe KA and Yanez JA. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?--Not as easy as 1, 2, 3. J Pharm Pharm Sci. 2004; 7:217-226.
34. Chen C and Bazan NG. Acetaminophen modifies hippocampal synaptic plasticity via a presynaptic 5-HT2 receptor. Neuroreport . 2003; 14: 743-747.
35. Ehrlich K., Sicking C., Respondek M and Peskar BM. Interaction of cyclooxygenase isoenzymes, nitric oxide, and afferent neurons in gastric mucosal defense in rats. J
Pharmacol Exp Ther .2004; 308:277-283.
36. Gryglewski RJ., Chlopicki S., Swies J. In vivo endothelial interaction between ACE and COX inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2005; 72:129-131.
37. Harris RC. The macula densa: recent developments. J. Hypertension. 1996; 14: 815–822
38. Stokes JB. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle. J. Clin. Invest. 1979; 64: 495–502
39. Dinchuk JE., Car BD., Focht RJ., Johnston JJ., Jaffee BD., Covington MB., Contel NR., Eng VM., Collins RJ., Czerniak PM., Gorry SA and Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378: 406–409
40. Morham SG., Langenbach R., Loftin CD., Tiano HF., Vouloumanos N., Jennette J C., Mahler JF., Kluckman KD., Ledford A., Lee CA and Smithies O. Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell. 1995; 83: 473–482
41. Cao C., Matsumura K., Yamagata K and Watanabe Y. Involvement of Cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am. J. Physiol. 1997; 272: 1712–1725
42. Matsumura K., Cao C., and Watanabe Y. Possible role of cyclooxygenase-2 in the brain vasculature in febrile response. Ann. N.Y. Acad. Sci. 1997; 813: 302–306
43. Taniguchi Y., Yokoyama K., Inui K., Deguchi Y., Furukawa K and Noda K. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur. J. Pharmacol. 1997; 330: 221–229.
44. Cao C., Matsumura K., and Watanabe Y. Induction of cyclooxygenase-2 in the brain by cytokines. Ann. N.Y. Acad. Sci. 1997; 813: 307–309
45. Bauer MK., Lieb K., Schulze-Osthoff K., Berger M., Gebicke Haerter P. J., Bauer J., and Fiebich BL. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem. 1997; 243: 726–731
46. Kaufmann WE., Worley PF., Taylor CV., Bremer M and Isakson PC. Cyclooxygenase-2 expression during rat neocortical development and in Rett syndrome. Brain Dev. 1997; 19: 25–34
47. Yamagata K., Andreasson K., Kaufmann W., Barnes C., and Worley P. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993; 11: 371–386
48. Kaufmann WE., Worley PF., Pegg J., Bremer M and Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. 1996; 93: 2317–2321
49. Tocco G., Freire-Moar J., Schreiber S., Sakhi S., Aisen P and Pasinetti G. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer’s disease. Exp. Neurol. 1997; 144: 339–349
50. Miettinen S., Fusco FR., Yrjanheikki J., Keinanen R., Hirvonen T., Roivainen R., Narhi M., Hokfelt T., and Koistinaho J. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc. Natl. Acad. Sci. 1997; 94: 6500–6505
51. Pasinetti GM and Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience. 1998; 87: 319–24.
52. Hoozemans JJ., Rozemuller AJ., Janssen I., De Groot CJ., Veerhuis R., Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol . 2001; 101:2–8
53. Yermakova A and O’Banion MK. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharmacol Res . 2000; 6:1755–1776.
54. McGeer PL., Schulzer M., McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996; 47:425–432.
55. Stewart WF., Kawas C., Corrada M., Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997; 48:626–632.
56. Chakraborty I., Das SK., Wang J and Dey SK. Developmental expression of the cyclooxygenase-1 and cyclooxygenase- 2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol. 1996; 16:107–122
57. Yang ZM., Das SK., Wang J., Sugimoto Y., Ichikawa A and Dey SK. Potential sites of prostaglandin actions in the peri implantation mouse uterus: differential expression and regulation of prostaglandin receptor genes. Biol. Reprod. 1997; 56: 368–379
58. Lim H and Dey S. K. Prostaglandin E-2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. Endocrinology. 1997; 138: 4599–4606
59. Lim H., Paria BC., Das SK., Dinchuk JE., Langenbach R., Trzaskos JM and Dey SK. Multiple female reproductive failures in cyclooxygenase-2 deficient mice. Cell. 1997; 91:197–208
60. Sugimoto Y., Yamasaki A., Segi E., Tsuboi K., Aze Y., Nishimura T., Oida H., Yoshida N., Ranaka R., Karsuyama M., Hasumoto K., Murata T., Hirata M., Ushikubi F., Negishi M., Ichikawa A and Narumiya S. Failure of parturition in mice lacking the prostaglandin F receptor. Science. 1997; 277: 681–683
61. Kawaguchi H., Pilbeam CC., Harrison JR and Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin. Orthop. Relat. Res. 1995; 313: 36–46
62. . Woodiel FN., Fall PM and Raisz LG. Anabolic effects of prostaglandins in cultured fetal rat calvariae: structure- activity relations and signal transduction pathway. J. Bone Miner. Res. 1996; 11: 1249–1255
63. Klein-Nulend J., Burger EH., Semeins CM., Raisz LG and Pilbeam CC. Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J. Bone Miner. Res. 1997; 12: 45–51
64. Pilbeam CC., Harrison JR and Raisz LG. Prostaglandins and bone metabolism. In Principles of Bone Biology Academic Press, New York .1996; 715– 728
65. Pilbeam CC., Fall PM., Alander CB and Raisz LG. Differential effects of nonsteroidal anti-inflammatory drugs on constituitive and inducible prostaglandin G/ H synthase in cultured bone cells. J. Bone Miner. Res. 1997; 12: 1198–1203
66. Allison AC., Chin RC and Cheng Y. Cyclooxygenase inhibitors vary widely in potency for preventing cytokine induced bone resorption. Ann. N.Y. Acad. Sci. 1993; 696: 303–306
67. Jeffcoat MK., Reddy MS., Moreland LW and Koopman WJ. Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. Ann. N.Y. Acad. Sci. 1993; 696: 292–302
68. Sato T., Morita I., Sakaguchi K., Nakahama K., and Murota S. Involvement of cyclooxygenase-2 in bone loss induced by interleukin-1b. Adv. Prostaglandin,
Thromboxane, Leukotriene Res. 1995; 23:445–447
69. Tai H., Miyaura C., Pilbeam CC., Tamura T., Ohsugi Y., Koishihara Y., Kubodera N., Kawaguchi H., Raisz LG and Suda T. Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology. 1997; 138: 2372–2379
70. Onoe Y., Miyaura C., Kaminakayashiki T., Nagai Y., Noguchi K., Chen QR., Seo, H., Ohta H., Nozawa S., Kudo I., and Suda T. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol. 1996; 156: 758–764
71. Tetradis S., Pilbeam CC., Liu Y., Herschman HR., and Kream BE. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic Adenosine 3*, 5*-monophosphate mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology. 1997; 138: 3594–3600
72. Tjandrawinata RR., Vincent VL and Hughes-Fulford M. Vibrational force alters mRNA expression in osteoblasts. FASEB J. 1997; 11: 493–497
73. Lands WE. The biosynthesis and metabolism of prostaglandins. Annu. Rev. Physiol. 1979; 41: 633–652
74. Fahn S., Przedborski S . Merritt's Neurology. Rowland L P., editor. Williams & Wilkins, New York: Lippincott; 2000; 679–693.
75. Przedborski S., Kostic V., Giladi N., Eidelberg D . Dopamine Receptors and Transporters. Sidhu A, Laruelle M, Vernier P. editors. New York: Dekker; 2003; 363–402.
76. Wyss-Coray T and Mucke L. Ibuprofen, inflammation and Alzheimer disease. Nat Med. 2000; 6: 973-974.
77. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A P., Chen C., Przedborski S. Ann Neurol.2001; 49: 176–185.
78. Andreasson KI., Savonenko A., Vidensky S., Goellner JJ., Zhang Y., Shaffer A., Kaufmann WE., Worley PF., Isakson P., Markowska AL . J. Neurosci; 2001; 21:8198– 8209.
79. Nogawa S., Zhang F., Ross ME., Iadecola C. Cyclo-oxygenase-2 gene. expression in neurons contributes to ischemic brain damage. J. Neurosci. 1997; 17: 2746–2755.
80. O'Banion MK. Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Crit. Rev. Neurobiol. 1999; 13:45-82.
81. Scheiman JM. NSAIDs,gastrointestinal injury, and cytoprotection. Gastroenterol. Clin. N. Am. 1996; 25: 279–298
82. Cohn SM., Schloemann S., Tessner T., Seibert K., and Stenson WF. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest. 1997; 99: 1367–1379
83. Simon LS. Biologic effects of nonsteroidal anti-inflammatory drugs. Curr. Opin.
Rheum. 1997; 9: 178–182
84. Giannella RA., Formal SB., Dammin GJ and Collins H. Pathogenesis of Salmonellosis. Studies of fluid secretion, mucosal invasion, and morphologic. J.
Clin. Investi. 1973; 52:441-453.
85. Eckmann L., Stenson WF., Savidge TC., Lowe DC., Barrett KE., Fierer J., Smith, JR and Kagnoff MF. Role of intestinal epithelial cells in the host secretor response to infection by invasive bacteria: bacterial entry induces epithelial prostaglandin H synthase-2 expression and prostaglandinE2 and F2a production. J. Clin. Invest. 1997; 100: 296–309
86. Hammerman C. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin. Perinatol. 1995; 22: 457–479
87. Richards JS., Fitzpatrick SL., Clemens JW., Morris JK., Alliston T and Sirois J. Ovarian cell differentiation: a cascade of multiple hormones, cellular signals, and regulated genes. Rec. Prog. Hormone Res. 1995; 50: 223–254
88. Richards J. Hormonal control of gene expression in the ovary. Endocr. Rev. 1994; 15: 725–751
89. Tsafriri A. Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Adv. Exp. Med. Biol. 1995; 377:121–140
90. Morris JK and Richards JS. An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells. J. Biol. Chem. 1996; 271: 16633–16643
91. Chakraborty I., Das SK., Wang J and Dey SK. Developmental expression of the cyclooxygenase-1 and cyclooxygenase- 2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol. 1996; 16: 107–122
92. Yang ZM., Das SK., Wang J., Sugimoto Y., Ichikawa A and Dey SK. Potential sites of prostaglandin actions in the periimplantation mouse uterus: differential expression and regulation of prostaglandin receptor genes. Biol. Reprod. 1997; 56: 368–379
93. Lim H and Dey SK. Prostaglandin E-2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. Endocrinology. 1997; 138: 4599–4606
94. Lim H., Paria BC., Das SK., Dinchuk JE., Langenbach R., Trzaskos, JM and Dey, SK. Multiple female reproductive failures in cyclooxygenase-2 deficient mice. Cell. 1997; 91:197–208
95. Sugimoto Y., Yamasaki A., Segi E., Tsuboi K., Aze Y., Nishimura T., Oida H., Yoshida N., Ranaka R., Karsuyama M., Hasumoto K., Murata T., Hirata M., Ushikubi F., Negishi M., Ichikawa A., and Narumiya S. Failure of parturition in mice lacking the prostaglandin F receptor. Science. 1997; 277: 681–683
96. O’Brien WF. The role of prostaglandins in labor and delivery. Clin. Perinatol. 1995; 22: 973–984
97. Zuckerman H., Reiss U and Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet. Gynecol. 1974; 44:87–792
98. Kawaguchi H., Pilbeam CC., Harrison JR and Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin. Orthop. Relat. Res. 1995; 313: 36–46
99. Woodiel FN., Fall, P. M., and Raisz, L. G. Anabolic effects of prostaglandins in cultured fetal rat calvariae: structure- activity relations and signal transduction pathway. J. Bone Miner. Res. 1996; 11: 1249–1255
100. Klein-Nulend J., Burger EH., Semeins CM., Raisz LG and Pilbeam CC. Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J. Bone Miner.Res. 1997; 12: 45–51
101. Pilbeam CC., Harrison JR and Raisz LG. Prostaglandins and bone metabolism. In Principles of Bone Biology. Bilezikian J., Raisz L. and Rodan G., (eds.), Academic Press, New York. 1996; 715–728.
102. Pilbeam CC., Fall PM., Alander CB and Raisz LG. Differential effects of nonsteroidal anti-inflammatory drugs on constituitive and inducible prostaglandin G/ H synthase in cultured bone cells. J. Bone Miner. Res. 1997; 12: 1198–1203
103. Allison AC., Chin RC and Cheng Y. Cyclooxygenase inhibitors vary widely in potency for preventing cytokine induced bone resorption. Ann. N.Y. Acad. Sci. 1993; 696: 303–306
104. Jeffcoat MK., Reddy MS., Moreland LW and Koopman WJ. Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. Ann. N.Y. Acad. Sci. 1993; 696: 292–302
105. Tai H., Miyaura C., Pilbeam CC., Tamura T., Ohsugi Y., Koishihara Y., Kubodera, N., Kawaguchi H., Raisz LG and Suda T. Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology. 1997; 138: 2372–2379
106. Onoe Y., Miyaura C., Kaminakayashiki T., Nagai Y., Noguchi K., Chen Q. R., Seo, H., Ohta H., Nozawa S., Kudo I., and Suda T. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol.1996;156: 758–764
107. Tetradis S., Pilbeam CC., Liu Y., Herschman HR and Kream BE. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic Adenosine 3*,5*-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 1997; 138: 3594–3600
108. Tjandrawinata RR., Vincent VL and Hughes-Fulford M. Vibrational force alters mRNA expression in osteoblasts. FASEB J. 1997; 11: 493–497
109. Lands WE. The biosynthesis and metabolism of prostaglandins. Annu. Rev.
Physiol. 1979; 41:633–652
110. Needleman P and Isakson PC. .The discovery and function of COX-2. J. Rheum. 1997; 24: 6–8
111. Anderson GD., Hauser SD., McGarity KL., Bremer ME., Isakson PC and Gregory SA. Selective inhibition of cylooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleuken 6 in rat adjuvant arthritis. J. Clin. Invest. 1996; 97: 2672–2679
112. Amin AR., Attur M., Patel RN., Thakker GD., Marshall PJ., Rediske J., Stuchin SA., Patel IR and Abramson SB. Super induction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: influence of nitric oxide. J. Clin. Invest. 1997; 99: 1231–1237
113. Kang RY., Freire-Moar J., Sigal E and Chu CQ. Expression of Cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br. J. Rheum. 1996; 35:711–718
114. Manfield L., Jang D and Murrell GA. Nitric oxide enhances Cyclooxygenase activity in articular cartilage. Inflamm. Res. 1996; 45: 254–258
115. Penning T., Talley J., Bertenshaw S., Carter J., Collins P., Docter S., Graneto M., Lee L., Malecha J., Miyashiro J., Rogers R., Rogier D., Yu S., Andersen G., Burton E., Cogburn J., Gregory S., Koboldt C., Perkins W., Seibert K., Veenhuizen A., Zhang Y and Isakson P. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase- 2 inhibitors: identification of 4-5-4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl. benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem.1997; 440:1347–1365
116. Lipsky PE and Isakson PC. Outcome of specificCOX-2 inhibition in rheumatoid arthritis. J. Rheumatol. 1997; 24: 9–14.
117. Dray A and Urban L. New pharmacological strategies for pain relief. Annu. Rev.
Pharmacol. Toxicol. 1996; 36: 253–280
118. Yamamoto T and Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res.1996; 739: 104–110
119. Cherng CH., Wong CS and Ho ST. Spinal actions of nonsteroidal anti-inflammatory drugs. Acta Anaesthesiol. Sinica. 1996; 34: 81–88
120. Cashman JN and McAnulty G. Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use. Drugs. 1995; 49: 51–70
121. Cashman JN. The mechanisms of action of NSAIDs analgesia. Drugs. 1996; 52: 13–23
122. Beiche F., Scheuerer S., Brune K., Geisslinger G., and Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996; 390: 165–169
123. Laird JMA., Herrero JF., Garcia de la Rubia, P and Cervero F. Analgesic activity of the novel COX-2 preferring NSAID, meloxicam, in mono-arthritic rats: central and peripheral components. Inflamm. Res.1997; 46: 203–210
124. Needleman P and Isakson PC. .The discovery and function of COX-2. J. Rheum. 1997; 24: 6–8
125. Anderson GD., Hauser SD., McGarity KL., Bremer ME., Isakson PC and Gregory SA. Selective inhibition of cylooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleuken 6 in rat adjuvant arthritis. J. Clin. Invest. 1996; 97: 2672–2679
126. DuBois RN., Abramson SB., Crofford L et al. Cyclooxygenase in biology and disease. FASEB J. 1998; 12: 1063–73.
127. Leahy KM., Ornberg RL., Wang Y., Zweifel BS., Koki AT., Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002;62: 625–31.
128. Gately S and Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004; 31: 2–11
129. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57–70.
130. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol .2000; 31: 403–5.
131. Ferrara N., Gerber HP., LeCouter J. The biology of VEGF and its receptors. Nat
Med. 2003; 9: 669–76.
132. Yuan A., Pan-Chyr Y., Kwen-Tay L. Tumoral COX-2 overexpression correlates with vascular endothelial growth factor (VEGF) expression and angiogenesis, and associated with short survival and early relapse in non small cell lung cancer. Proc Am Assoc Cancer Res. 2003; 44: 928
133. Daniel TO., Liu H., Morrow JD., Crews BC., Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2 dependent endothelial migration and angiogenesis.Cancer Res. 1999; 59: 4574–7
134. Inoue H., Takamori M., Shimoyama Y., Ishibashi H., Yamamoto S., Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol. 2002; 136: 287–95.
135. Murohara T., Horowitz JR., Silver M et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacycline. Circulation. 1998; 97: 99–107.
136. Nelson AR., Fingleton B., Rothenberg ML., Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000; 18: 1135–49.
137. Callejas NA., Casado M., Diaz-Guerra MJ., Bosca L., Martin-Sanz P. Expression of cyclooxygenase-2 promotes the release of matrix methaloproteinases-2 and -9 in fetal rats hepatocytes. Hepatology. 2001; 33: 860–7.
138. Voeset EE., Kenyon BM., O‘reily MS., Truitt G., D’Amatto RJ., Folkman J. Inhibition of angiogenesis in vivo by interleukin. J Natl Cancer Ins.t 1995; 87: 581–6.
139. Stolina M ., Sharma S., Lin Y et al. Specific inhibition of cyclooxygenase- 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000; 164: 361–70.
140. Tsuji M and DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase 2. Cell .1995; 83: 493–501.
141. Liu CH., Chang SH., Narko K et al. Overexpression of cyclooxygenase- 2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001; 277: 18563–9.
142. Sheng H., Shao J., Morrow JD et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58: 362–6.
143. Arico S., Pattingre S., Bauvy C et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in human colon cancer HT-29 cell line. J Biol Chem. 2002; 277: 27613–21.
144. Altorki NK., Subbaramaiah K., Dannenberg AJ. COX-2 inhibition in upper aerodigestive tract tumors. Semin Oncol. 2004; 31: 30–5.
145. Dannenberg AJ., Altorki NK., Boyle JO., Dang C., Howe LR., Weksler BB. Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2: 544–51.
146. Yoshimura R., Sano H., Mitsuhashi M., Kohno M., Chargui J., Wada S. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol. 2001; 165: 1468–72.
147. Ristimaki A., Sivula A., Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62: 632–5.
148. Dicker AP., Williams TL., Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol. 2001; 24: 438–42.
149. Ma L., del Soldato P., Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad
Sci USA. 2002; 99: 13243–7.
150. Wei D., Wang L., He Y. Celecoxib inhibits vascular endothelia growth factor expression by targeting Sp1 transcription factor and reduces human pancreatic cancer angiogenesis and metastasis. Proc Am Assoc Cancer Res. 2003; 44: 633
151. Wiese FW., Thompson PA., Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis. 2001; 21: 5–10.
152. Cuccurullo C., Fazia ML., Mezzetti A., Cipollone F. “COX-2 Expression in Atherosclerosis: The Good, the Bad or the Ugly?”Current Medicinal Chemistry. 2007; 14 : 1595-1605
153. Kujubu DA., Fletcher BS., Varnum BC., Lim RW., Herschman HR. TIS 10, a phorbol ester tumor promoter—inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 1991; 266: 12866–12872
154. Eberhart CE., Coffey RJ., Radhika A., Giardiello FM., Ferrenbach S., DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107: 1183–1188
155. Tsujii M., Kawano S., DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci. 1997; 94: 3336–3340
156. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin
Lab Sci .2000; 30: 3–21
157. Lukiw WJ and Bazan NG. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res .2000; 25: 1173–84
158. Reis ED., Roque M., Dansky H., Fallon JT., Badimon JJ., Cordon-Cardo C., Shiff SJ., Fisher EA. Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc Natl Acad Sci .2000; 97: 12764–12769
159. Schonbeck U., Sukhova GK., Graber P., Coulter S., Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J. Pathol. 1999; 155: 1281–1291
160. Baker CSR., Hall RJC., Evans TJ et al. Cyclooxygenase-2 is widely expressed atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999; 19: 646–655
161. Belton O., Byrne D., Kearney D., Leahy A., Fitzgerald D. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000; 102: 840–845
162. Fitzgerald GA., Pedersen AK., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983; 67: 1174–1177
163. Rosenfeld ME., Khoo JC., Miller E., Parthasarathy S., Palinski W., Witzum JL. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins and contain oxidation-specific lipid protein adducts. J Clin Invest. 1991; 87: 90–99
164. Guyen-Khoa T., Massy ZA., Witko-Sarsat V., Canteloup S., Kebede M., Lacour B., Drüeke T éatrice Descamps-Latscha B. Oxidized low-density lipoprotein induces macrophage respiratory burst via its protein moiety: a novel pathway in atherogenesis? Biochem Biophys Res Commun. 1999; 263: 804–809
165. Arai H., Nagano Y., Narumiya S., Kita T. Decreased arachidonate metabolism in mouse peritoneal macrophages after foam cell transformation with oxidized low-density lipoproteins. J Biochem. 1992; 112: 482–487
166. Hamilton TA., Major JA., Chisholm GM. The effects of oxidized low density lipoproteins on inducible mouse macrophage gene expression are gene and stimulus dependent. J Clin Invest. 1995; 95: 2020–2027
167. Eligini S., Colli S., Basso F., Sironi L., Tremoli E. Oxidized low-density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages. Arterioscler Thromb Vasc Biol. 1999; 19: 1719–1725
168. Moore RN., Pitruzello FJ., Deana DG., Rouse BT. Endogenous regulation of macrophage proliferation and differentiation by E prostaglandins and interferon alpha/beta. Lymphokine Res. 1985; 4: 43–50
169. Yaari S., Goldbourt U., Even-Zohar S., Neufeld HN. HDL and total cholesterol: association with total, cardiovascular and cancer mortality in a seven year prospective study of 10,000 men. Lancet. 1981; 1: 1011–1015
170. Cockerill GW., Rye KA., Gamble JR., Vadas MA., Barter PJ. High density lipoproteins inhibit cytokine induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995; 15: 1987–1994
171. Fleisher LN., Tall AR., Witt LD., Miller RW., Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoprotein. J Biol Chem. 1982; 257: 6653–6655
172. Cockerill GW., Saklatvala J., Ridley SH., Yarwood H., Miller NE., Oral B. Nithyanathan S., Taylor G. and Haskard DO. High density lipoproteins differentially modulate cytokine induced expression of E-selectin and COX-2. Arterioscler Thromb Vasc Biol. 1999; 19: 910–917
173. Murata T., Ushikubi F., Matsuoka T., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Ohishi S., Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997; 388: 678–682
174. McAdam BF., Catella-Lawson F., Mardini IA ., Kapoor S., Lawson JA., Fitz Gerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA1999; 96: 272–277
175. Pratico D., Tillmann C., Zhi-Bing Z., Hongwei L., Fitz Gerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci, USA. 2001; 98: 3358– 3363
176. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz MB., Hawkey CJ., Hochberg MC., Kvien TK., Schnitzer TJ. VIGOR Study Group, comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520–1528
177. Boers M. NSAIDs and selective COX-2 inhibitors: competition gastroprotection and cardioprotection. Lancet. 2001; 357: 1222–1223
178. Linton., MacRae F., Fazio., Sergio. Current Opinion in Lipidology. 2002; 13: 497-504.

Author Information

Asma Saqib
Department of Biochemistry, Central College Campus, Bangalore University

Chandrakant S. Karigar
Department of Biochemistry, Central College Campus, Bangalore University

Your free access to ISPUB is funded by the following advertisements:

Advertisement
BACK TO TOP
  • Facebook
  • Google Plus

© 2013 Internet Scientific Publications, LLC. All rights reserved.    UBM Medica Network Privacy Policy